Qilan Nangbing Drink veterinary-grade active substance is incorporated into drinking water medication for poultry and swine via a soluble powder intermediate prepared by wet granulation followed by fluidised-bed drying at an inlet air temperature of 55°C to 65°C and an exhaust air temperature not exceeding 40°C. Because published stability data for this specific API in the described drinking-water matrix are limited, the following release targets are treated as process-development specifications requiring confirmation under VICH GL5. The granulation liquid contains 10.0% w/w active substance, 0.2% w/w tetrasodium EDTA, anhydrous citric acid sufficient to give a reconstituted solution pH of 3.8–4.2, and povidone K30 at 1.5% w/w as binder. After drying, the granules are milled through a 1.0 mm screen and blended with spray-dried maltodextrin to a final active substance concentration of 5.0% w/w in a 600 L ribbon blender operated at 18 rpm for 12 min; sieve analysis through 250 µm shows not more than 5.0% retained oversize. The powder is filled into aluminium foil laminate sachets at 20°C–25°C and ≤40% relative humidity. For low-density granulated powders of this class, moisture uptake above 2.5% w/w has been observed on pilot-scale filling lines to delay complete reconstitution beyond 2 min in water at 15°C; each production batch of this API must be confirmed because published data for this specific configuration is limited. Field dilution at 0.5 g/L to 1.0 g/L is used for mass administration; the product is first dissolved in warm water at 35°C in a 1:50 stock solution ratio. Water hardness above 250 mg/L CaCO₃ reduces dissolution rate unless the tetrasodium EDTA concentration is increased to 0.35% w/w. Analytical release for this dosage form includes assay by HPLC under Ph. Eur. 2.2.29, loss on drying by Ph. Eur. 2.2.32 at 105°C for 2 h, and related substances per VICH GL3. For low-dose veterinary water-soluble powders, stock solution viscosity below 25 mPa·s at 25°C is typically required to prevent diaphragm medicator pump cavitation in high-throughput poultry buildings; viscosity is checked with a Brookfield DV2T viscometer using spindle LV-1 at 60 rpm. Compliance for the finished veterinary medicinal product is handled under Regulation (EU) 2019/6, and residue surveillance follows Council Directive 96/23/EC where the active substance is used in food-producing species.

Which Premix Dilution Pattern Prevents Segregation in 0.2% Medicated Feed?

In medicated feed applications, Qilan Nangbing Drink veterinary-grade API is not added directly to final feed because the target inclusion of 0.2% w/w creates a low-dose segregation risk in horizontal feed mixers. Published data for this specific API in medicated premixes is limited; the following cascade is a representative process-development scheme based on low-dose veterinary API handling and must be verified by blend uniformity analysis. The active substance is first converted into a 20.0% w/w premix using a geometric dilution sequence in which each stage reduces active concentration by a factor of 5. Stage 1 combines 20.0 kg active substance with 80.0 kg spray-dried lactose carrier in a 300 L twin-shell blender at 12 rpm for 15 min; the lactose is pre-sieved through 250 µm and dried to loss on drying ≤ 1.5%. Stage 2 takes 20.0 kg of stage-1 premix and dilutes with 80.0 kg ground corn passed through 800 µm in a 600 L ribbon blender at 20 rpm for 10 min. Stage 3 takes 20.0 kg of stage-2 material and dilutes with 80.0 kg limestone carrier with particle size 100–300 µm in a 1000 L double-ribbon mixer at 18 rpm for 8 min. The cascade parameters are summarised below.

Segregation is controlled by keeping the bulk density differential between the active substance and each carrier below 0.15 g/cm³ and by filling the final mixer to 60–70% of gross volume. Field experience with low-dose veterinary premixes in a 1000 L mixer shows that filling above 75% volume reduces axial mixing and leaves a coefficient of variation above 5.0% in ten samples taken according to Ph. Eur. 2.9.40; accordingly, the same sampling plan is applied to this API until formulation-specific data are generated. For electrostatic charge dissipation, the final premix is discharged through an earthed rotary valve and packed into antistatic 25 kg paper-polyethylene bags at ≤45% relative humidity. The finished medicated feed is manufactured at 0.2% w/w inclusion and must comply with the medicated feed requirements of Regulation (EU) 2019/6 and with the analytical designations under Commission Regulation (EC) 152/2009 for the official control of feed. Addition of the premix to pelleted feed is permitted only when the post-pelleting temperature at the pellet mill die is maintained below 70°C; published thermal degradation data for this specific API at higher conditioning temperatures is limited, so each formulation must be verified by assay before release. The premix should not be combined with alkaline carriers such as sodium bicarbonate unless the finished feed is consumed within 48 h, because prolonged contact at pH above 8.0 has been shown in accelerated stability cabinets at 40°C/75% RH to increase the rate of hydrolytic degradation for structurally related veterinary active substances.

Parenteral solutions of Qilan Nangbing Drink veterinary-grade active substance are prepared under aseptic conditions in an EU GMP Annex 1 cleanroom corresponding to ISO 14644-1 Class 5 at rest, with the active substance dissolved in Water for Injections at 35°C–40°C under nitrogen blanketing because the molecule shows oxidative discoloration when held at elevated temperature in air. Published filter compatibility and terminal sterilisation data for this specific API are limited; the following parameters are process-development targets and require validation for each batch size. The solution is adjusted to pH 6.8–7.2 with 0.1 M sodium hydroxide or hydrochloric acid, and sodium chloride is added to reach an osmolality of 285–310 mOsm/kg by Ph. Eur. 2.2.35. The batch is passed through a 0.45 µm polyethersulfone prefilter and then through two serial 0.22 µm PVDF sterilising-grade filters with integrity testing by bubble point before filling. Terminal sterilisation at 121°C for 15 min is not applied unless the specific batch has confirmed thermal stability; aseptic processing is the default route because the active substance contains heat-labile moieties. Filling is performed on a 12-head peristaltic dosing line into amber Type I glass vials at 10 mL to 100 mL nominal volume under Grade A unidirectional airflow. After filling, sterility is tested by Ph. Eur. 2.6.1, bacterial endotoxin by Ph. Eur. 2.6.14 with a limit of 0.5 EU/mg, and visible particles by Ph. Eur. 2.9.20. In production-scale aseptic filling of low-concentration parenteral solutions, filter flux decay is a known failure mode when the active substance is not fully dissolved before filtration; a pre-filtration turbidity above 5 NTU measured by a Hach TL2350 turbidimeter has been associated with premature filter blocking at 15–20 L/m² throughput in similar formulations. The solution should not be stored in contact with natural rubber stoppers because of potential leachable interactions; bromobutyl stoppers coated with fluoropolymer are specified. Published data for this API in multidose containers with benzyl alcohol preservative are limited, so single-dose units are recommended unless compatibility studies are generated.

When Tablets Are Required for Companion Animal Dose Titration

Tableting of Qilan Nangbing Drink veterinary-grade active substance is directed toward divisible oral tablets for dogs and cats in strength bands of 5 mg, 10 mg, and 25 mg. Direct compression is feasible only when the active substance median particle size D50 is below 75 µm and the bulk density is above 0.55 g/cm³; otherwise wet granulation is required. Published data for this specific API in tablet dosage forms are limited, so the following formula is a development starting point rather than a licensed composition. A production formula uses 20.0% w/w active substance, 68.0% w/w dibasic calcium phosphate dihydrate, 10.0% w/w microcrystalline cellulose PH-102, 1.5% w/w crospovidone, 0.5% w/w magnesium stearate, and 2.0% w/w hydroxypropyl methylcellulose E5 as binder solution at 5% w/w solids in purified water. Granulation is carried out in a 300 L high-shear mixer with impeller speed 250 rpm and chopper speed 1500 rpm; water addition is stopped when the granulate reaches a torque value corresponding to an end-point power of 12–14 kW on the mixer main drive. The granules are dried at 50°C inlet air in a fluid-bed drier to a final loss on drying of 1.8–2.2% and then milled through a 0.8 mm screen. Compression is performed on a 45-station rotary tablet press with a main compression force of 18–22 kN and a pre-compression force of 6 kN, targeting tablet hardness of 90–120 N and friability below 0.5% by Ph. Eur. 2.9.7. Content uniformity follows Ph. Eur. 2.9.40, and dissolution is tested using USP 711 apparatus 2 at 50 rpm in 900 mL of pH 4.5 acetate buffer with a Q value of 75% in 45 min. The comparison between direct compression and wet granulation for this active substance is summarised below.

On a 45-station rotary press, dwell times below 10 ms have been observed in tablet development for low-dose veterinary APIs to produce capping at hardness above 100 N, so main compression speed is limited to 35 rpm unless a pre-compression dwell extension is used. The tablet formulation should avoid unmodified starch and should not be film-coated with aqueous hydroxypropyl methylcellulose above 60°C inlet air until forced-degradation data for this specific API confirm stability; if the des-formyl degradation product remains below 0.2% under VICH GL3 conditions, the coating step may be introduced.

Extruded Granule and Capsule Fill Parameters for Daily Oral Dosing

Qilan Nangbing Drink veterinary-grade API is prepared for capsule-based oral therapy in adult dogs by wet granulation followed by extrusion-spheronisation to produce dense pellets that permit reproducible fill weights on automatic capsule machines. Published process data for this specific API in extruded pellet form are limited; the following conditions are development targets requiring confirmation by design of experiments. The granulation liquid consists of 15.0% w/w active substance, 5.0% w/w microcrystalline cellulose PH-101, 3.0% w/w povidone K30 in purified water, and 0.5% w/w sodium lauryl sulfate as wetting agent. The wet mass is extruded through a dome granulator equipped with a 0.8 mm screen at 40 rpm, then spheronised at 700 rpm for 3 min on a cross-hatch plate to produce pellets with an aspect ratio below 1.2. Drying is carried out in a fluid-bed drier at 45°C to a moisture content of 1.0–1.5% by Ph. Eur. 2.2.32, and the dried pellets are sieved to collect the 600–1000 µm fraction. The pellets are filled into size 1 hydroxypropyl methylcellulose capsules at a target fill weight of 200 mg per capsule using a dosing pin capsule filler operating at 60,000 capsules/h; vacuum-assisted pin height is adjusted to achieve a weight variation of not more than ±5% across 20 consecutive capsules. Dissolution release follows Ph. Eur. 2.9.3 using a basket apparatus at 100 rpm in 900 mL of pH 6.8 phosphate buffer with 75% release at 30 min. For this class of extruded pellets, brittle fracture during six-month shelf storage at 25°C/60% RH has been controlled by adding 2.0% w/w polyethylene glycol 6000 to the granulation liquid, which reduces breakage when pellets are dropped 50 cm onto a stainless-steel surface; product-specific confirmation for this API is required. This capsule presentation is not recommended for cats with a body weight below 2 kg because the fixed fill weight does not permit safe dose reduction without opening the capsule; extemporaneous reformulation into a liquid oil suspension is not validated and published data for such customisation is limited.

Injectable Freeze-Dried Formulations Demand pH and Osmolality Control

For parenteral administration where long-term room-temperature storage is required, Qilan Nangbing Drink veterinary-grade API is lyophilised as a sterile powder in 10 mL Type I glass vials with a fill volume of 2.0 mL. The pre-lyophilisation solution contains 50.0 mg/mL active substance, 40.0 mg/mL mannitol, 10.0 mg/mL trehalose dihydrate, and sodium citrate buffer to pH 6.5. Published data for this specific formulation is limited; the cycle parameters below represent process-development targets that must be confirmed by thermal characterisation and freeze-drying microscopy. The solution is filtered through 0.22 µm sterilising filters, filled into vials, and loaded onto a shelf lyophiliser with shelf fluid inlet temperature controlled to -45°C. Freezing is performed at a ramp of 0.5°C/min to -45°C and held for 3 h; primary drying is executed at 0.15 mbar chamber pressure with shelf temperature raised stepwise from -30°C to -5°C over 24 h; secondary drying at 30°C for 8 h reduces residual moisture to ≤1.0% by Ph. Eur. 2.5.12. The lyophilised cake is sealed under vacuum with bromobutyl stoppers and certified for sterility by Ph. Eur. 2.6.1, bacterial endotoxin by Ph. Eur. 2.6.14, and reconstitution time by adding 2.0 mL Water for Injections; a well-formed cake disperses in ≤60 s with gentle swirling. The product temperature during primary drying must remain below the glass transition of the maximally freeze-concentrated solute, which is measured for each batch by differential scanning calorimetry; if the measured value is above -35°C, primary drying shelf temperature must be lowered accordingly to avoid microcollapse. The formulation should not be reconstituted with bacteriostatic water containing benzyl alcohol unless compatibility has been established; the lyophilised powder should be protected from light. Analytical release includes pH after reconstitution 6.3–6.8, osmolality 300–350 mOsm/kg, and related compounds by HPLC with a specified unknown impurity limit of ≤0.10%.